SHC: Sotera Health Forward P/S Multiple

Corporate company logo of Nordion (SHC)

Sotera Health Company (SHC) is implementing automated radiation sterilization, eliminating manual labor. High regulatory barriers ensure absolute customer loyalty. The large-scale deployment of AI systems optimizes quality control. The forward P/S multiple reflects the dynamics of market expectations, with the current level sitting around 2.20, allowing for an assessment of the ratio between market capitalization and projected revenue.

SHC soterahealth.com: Forward Price to Sales in the range 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for Sotera Health Company (SHC)

- stock price and consensus target price:
Summary company analysis:soterahealth.com SHC
Manufactured products of Nordion

The forward P/S ratio compares the current market value of Sotera Health Company (SHC) with the expected revenue for the following year, determining the premium investors are willing to pay for future earnings. Within the oligopoly of the sterilization market, the forward P/S level reflects market confidence in the company's ability to maintain long-term contracts with pharma behemoths despite stringent environmental regulations.

Competitor analysis

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS - Forward P/S Multiple|RVTY (Revvity) - Forward Price-to-Revenue Multiple|Bio-Rad - Forward Price to Sales|Price-to-Projected Revenue Ratio anbio.com|Market Cap to Future Revenue Ratio QuidelOrtho Inc. QDEL|Forward P/S Multiple OPK|CareDx - Market Cap to Projected Revenue|Forward P/S Multiple MRVI (Maravai LifeSciences Holdings)|Price to Expected Revenue Ratio FLGT (Fulgent Corp)|LAB: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Cytek Corp CTKB|OSUR (OraSure Technologies Inc) - Forward Price-to-Revenue Multiple|Forward Price-to-Revenue Multiple Exagen Inc.|Forward Price-to-Revenue Multiple MDXH|LUCD - Projected Price to Revenue|Price-to-Projected Revenue Ratio Prenetics (PRE)|Price-to-Projected Revenue Ratio IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Forward Price-to-Revenue Multiple|prophaselabs.com - Price-to-Projected Revenue Ratio|AIMD - Price-to-Projected Revenue Ratio|Co-Diagnostics Inc (CODX) - Forward Price-to-Revenue Multiple|HSCS: Forward P/S Multiple|BMRA - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CDIO|Market Cap to Future Revenue Ratio onconetix.gcs-web.com ONCO|Price-to-Projected Revenue Ratio Virax Biolabs (VRAX)|Price to Expected Revenue Ratio BJDX|Price-to-Projected Revenue Ratio Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Projected Revenue|Market Cap to Future Revenue Ratio FRES|Market Cap to Future Revenue Ratio GTG Labs (GENE)|ME (23andme.com) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Inc